Table of Contents

1 Plerixafor Market Overview

• 1.1 Product Overview and Scope of Plerixafor
• 1.2 Classification of Plerixafor by Types
  • 1.2.1 Global Plerixafor Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Plerixafor Revenue Market Share by Types in 2018
  • 1.2.3 24MG/1.2ML
  • 1.2.4 Type II
• 1.3 Global Plerixafor Market by Application
  • 1.3.1 Global Plerixafor Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Non-Hodgkin's lymphoma (NHL) Patients
  • 1.3.3 Multiple myeloma (MM) Patients
• 1.4 Global Plerixafor Market by Regions
  • 1.4.1 Global Plerixafor Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Plerixafor Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Plerixafor Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Plerixafor Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Plerixafor Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Plerixafor Status and Prospect (2014-2024)
• 1.5 Global Market Size of Plerixafor (2014-2024)

2 Manufacturers Profiles

• 2.1 sanofi-aventis
  • 2.1.1 Business Overview
  • 2.1.2 Plerixafor Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 sanofi-aventis Plerixafor Revenue, Gross Margin and Market Share (2017-2018)

3 Global Plerixafor Market Competition, by Players

• 3.1 Global Plerixafor Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Plerixafor Players Market Share
  • 3.2.2 Top 10 Plerixafor Players Market Share
• 3.3 Market Competition Trend

4 Global Plerixafor Market Size by Regions

• 4.1 Global Plerixafor Revenue and Market Share by Regions
• 4.2 North America Plerixafor Revenue and Growth Rate (2014-2019)
• 4.3 Europe Plerixafor Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Plerixafor Revenue and Growth Rate (2014-2019)
• 4.5 South America Plerixafor Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Plerixafor Revenue and Growth Rate (2014-2019)

5 North America Plerixafor Revenue by Countries

• 5.1 North America Plerixafor Revenue by Countries (2014-2019)
• 5.2 USA Plerixafor Revenue and Growth Rate (2014-2019)
• 5.3 Canada Plerixafor Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Plerixafor Revenue and Growth Rate (2014-2019)

6 Europe Plerixafor Revenue by Countries

• 6.1 Europe Plerixafor Revenue by Countries (2014-2019)
• 6.2 Germany Plerixafor Revenue and Growth Rate (2014-2019)
• 6.3 UK Plerixafor Revenue and Growth Rate (2014-2019)
• 6.4 France Plerixafor Revenue and Growth Rate (2014-2019)
• 6.5 Russia Plerixafor Revenue and Growth Rate (2014-2019)
• 6.6 Italy Plerixafor Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Plerixafor Revenue by Countries

• 7.1 Asia-Pacific Plerixafor Revenue by Countries (2014-2019)
• 7.2 China Plerixafor Revenue and Growth Rate (2014-2019)
• 7.3 Japan Plerixafor Revenue and Growth Rate (2014-2019)
• 7.4 Korea Plerixafor Revenue and Growth Rate (2014-2019)
• 7.5 India Plerixafor Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Plerixafor Revenue and Growth Rate (2014-2019)

8 South America Plerixafor Revenue by Countries

• 8.1 South America Plerixafor Revenue by Countries (2014-2019)
• 8.2 Brazil Plerixafor Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Plerixafor Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Plerixafor Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Plerixafor by Countries

• 9.1 Middle East and Africa Plerixafor Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Plerixafor Revenue and Growth Rate (2014-2019)
• 9.3 UAE Plerixafor Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Plerixafor Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Plerixafor Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Plerixafor Revenue and Growth Rate (2014-2019)

10 Global Plerixafor Market Segment by Type

• 10.1 Global Plerixafor Revenue and Market Share by Type (2014-2019)
• 10.2 Global Plerixafor Market Forecast by Type (2019-2024)
• 10.3 24MG/1.2ML Revenue Growth Rate (2014-2024)
• 10.4 Type II Revenue Growth Rate (2014-2024)

11 Global Plerixafor Market Segment by Application

• 11.1 Global Plerixafor Revenue Market Share by Application (2014-2019)
• 11.2 Plerixafor Market Forecast by Application (2019-2024)
• 11.3 Non-Hodgkin's lymphoma (NHL) Patients Revenue Growth (2014-2019)
• 11.4 Multiple myeloma (MM) Patients Revenue Growth (2014-2019)

12 Global Plerixafor Market Size Forecast (2019-2024)

• 12.1 Global Plerixafor Market Size Forecast (2019-2024)
• 12.2 Global Plerixafor Market Forecast by Regions (2019-2024)
• 12.3 North America Plerixafor Revenue Market Forecast (2019-2024)
• 12.4 Europe Plerixafor Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Plerixafor Revenue Market Forecast (2019-2024)
• 12.6 South America Plerixafor Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Plerixafor Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology

Plerixafor (INN and USAN, trade name Mozobil) is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream.

Scope of the Report:
The global Plerixafor market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Plerixafor.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Plerixafor market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Plerixafor market by product type and applications/end industries.

Market Segment by Companies, this report covers
sanofi-aventis

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
24MG/1.2ML
Type II

Market Segment by Applications, can be divided into
Non-Hodgkin's lymphoma (NHL) Patients
Multiple myeloma (MM) Patients